



THE UNIVERSITY OF
TOLEDO
1872

SUSCEPTIBILITY PATTERNS OF COMMON ISOLATES

JUNE 2016 – DECEMBER 2016

UPDATED 06/01/2017

Testing performed on the BD Phoenix 100 Automated System

%SUSCEPTIBILITY OF COMMON GRAM POSITIVE ISOLATES

Inpatient (not-critical care)

June 2016 – December 2016

Organism	Total # Tested	Ampicillin	Benzylopenicillin	Ceftriaxone	Clindamycin	Gentamicin	Linezolid	Oxacillin	Rifampicin	Tetracycline	Trimethoprim/Sulfamethoxazole	Vancomycin
Staphylococcus aureus (MSSA AND MRSA)	83		0%		69%	96%	100%	51%	100%	93%	92%	100%
MRSA	41				51%	95%	100%		100%	88%	88%	100%
Coagulase-negative Staphylococcus	40		0%		45%	85%	100%	33%	97%	88%		100%
Enterococcus faecalis	56	100%	100%				98%			22%		98%
Enterococcus faecium	15	0%	0%				100%			14%		20%
Streptococcus pneumoniae	1		100%	100%			100%			100%		100%

*- Interpret with caution when the number of isolates is lower than 30.

Grayed-out boxes represent either unavailable data or inappropriate bug/drug combinations

%SUSCEPTIBILITY OF COMMON GRAM POSITIVE ISOLATES

MICU/SICU

June 2016 – December 2016

Organism	Total # Tested	Ampicillin	Benzylopicillin	Ceftriaxone	Clindamycin	Gentamicin	Linezolid	Oxacillin	Rifampicin	Tetracycline	Trimethoprim/Sulfamethoxazole	Vancomycin
Staphylococcus aureus (MSSA AND MRSA)	53		0%		59%	100%	100%	60%	98%	90%	88%	100%
MRSA	21				29%	100%	100%		95%	81%	81%	100%
Coagulase-negative Staphylococcus	10		0%		40%	70%	90%	10%	90%	90%		100%
Enterococcus faecalis	17	100%	100%				100%			25%		100%
Enterococcus faecium	6	0%	0%				100%			20%		0%
Streptococcus pneumoniae	3		100%	100%			100%			100%		100%

*- Interpret with caution when the number of isolates is lower than 30.

Grayed-out boxes represent either unavailable data or inappropriate bug/drug combinations

%SUSCEPTIBILITY OF COMMON GRAM NEGATIVE ISOLATES

Inpatient (not-critical care)

June 2016 – December 2016

Organism	Total # Tested	Aztreonam	Amikacin	Gentamicin	Tobramycin	Ampicillin	Amp/Sulbactam	Piperacillin/Tazobactam	Meropenem	Cefazolin	Cefepime	Ceftriaxone	Ciprofloxacin	Trimethoprim/Sulfamethoxazole	% ESBL Positive
Acinetobacter baumannii	4		100%	75%	75%		50%				75%		50%		
Enterobacter cloacae	19	63%	100%	95%	95%				100%		95%	63%	79%	84%	
Enterobacter aerogenes	3	100%	100%	100%	100%				100%		100%	100%	100%	100%	
Escherichia coli	97	89%	100%	92%	91%	41%	46%	93%	99%	76%	89%	86%	65%	63%	7%
Klebsiella pneumoniae	59	85%	100%	95%	85%		66%	86%	98%	78%	85%	85%	75%	75%	13%
Proteus mirabilis	34	100%	100%	68%	65%	88%	88%	100%		85%	97%	97%	56%	65%	
Pseudomonas aeruginosa	36		97%	86%	86%			72%	83%		92%		57%		

*- Interpret with caution when the number of isolates is lower than 30.

Grayed-out boxes represent either unavailable data or inappropriate bug/drug combinations

%SUSCEPTIBILITY OF COMMON GRAM NEGATIVE ISOLATES

MICU/SICU

June 2016 – December 2016

Organism	Total # Tested	Aztreonam	Amikacin	Gentamicin	Tobramycin	Ampicillin	Amp/Sulbactam	Piperacillin/Tazobactam	Meropenem	Cefazolin	Cefepime	Ceftriaxone	Ciprofloxacin	Trimethoprim/Sulfamethoxazole	% ESBL Positive
Acinetobacter baumannii	7		57%	57%	57%		57%				86%		43%		
Enterobacter cloacae	7	43%	100%	71%	57%				86%		57%	43%	57%	57%	
Enterobacter aerogenes	5	60%	100%	100%	100%				100%		100%	60%	100%	100%	
Escherichia coli	36	89%	100%	86%	89%	39%	44%	100%	100%	81%	89%	89%	53%	81%	9%
Klebsiella pneumoniae	31	74%	100%	90%	84%		61%	84%	100%	68%	74%	74%	74%	74%	9%
Proteus mirabilis	9	100%	100%	56%	56%	78%	89%	100%		89%	100%	100%	33%	33%	
Pseudomonas aeruginosa	34		100%	91%	91%			71%	65%		71%		65%		

*- Interpret with caution when the number of isolates is lower than 30.

Grayed-out boxes represent either unavailable data or inappropriate bug/drug combinations